Stockreport

Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF Gilead Sciences, Inc. 's GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased 7% year over year to $1.8 billion (in 202 [Read more]